Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on LinkedIn:
“The Phase 3 COMPETE trial shows 177Lu-edotreotide significantly improves PFS vs everolimus in GEP-NETs.
- 23.9 vs 14.1 months; HR 0.67
- TEAEs: 82.5% vs 97%
A major step forward!”